AR076836A1 - Inhibidores del canal de potasio medular externo renal - Google Patents
Inhibidores del canal de potasio medular externo renalInfo
- Publication number
- AR076836A1 AR076836A1 ARP100101504A AR076836A1 AR 076836 A1 AR076836 A1 AR 076836A1 AR P100101504 A ARP100101504 A AR P100101504A AR 076836 A1 AR076836 A1 AR 076836A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- independently selected
- 3alkyl
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrane Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Los compuestos de formula 1 son utiles como diuréticos y natriuréticos y por lo tanto son utiles para la terapia y la profilaxis de trastornos resultantes de una retencion de sales y agua excesiva, incluyendo enfermedades cardiovasculares tales como hipertension e insuficiencia cardiaca cronica y aguda. Reivindicacion 1: Un compuesto que tiene la formula estructural (1) y las sales farmacéuticamente aceptables del mismo, en el que formula (2) representa un anillo heterocíclico seleccionado entre el grupo que consiste en el grupo de formulas (3); Z1 se selecciona entre el grupo que consiste en formulas (4); Z2 se selecciona entre el grupo que consiste en formulas (5); X se selecciona entre el grupo que consiste en -H, -OH, -Oalquilo C1-3, -F, oxo, NH2 y -CH3; Y se selecciona entre el grupo que consiste en -H, -OH, -Oalquilo C1-3, -F, oxo, NH2 y -CH3; cada uno de X1 e Y1 se selecciona independientemente entre el grupo que consiste en -H y -CH3; cada uno de X2 e Y2 es -O-; con la condicion de que cuando X sea oxo entonces X1 esté ausente y cuando Y sea oxo entonces Y1 esté ausente; y con la condicion adicional de que cuando ni X2 ni Y2 estén presentes, entonces al menos uno de X e Y se seleccione entre el grupo que consiste en -OH, -Oalquilo C1-3, -F y oxo; cada uno de R1 y R2 se selecciona independientemente entre el grupo que consiste en -H, -halo, -cicloalquilo C3-6, -OR8, -SR8, -SOR8, -SO2R8, -(CH2)nOR8 y alquilo C1-6 opcionalmente sustituido con 1-3 de -F; uno de R3a y R3b se selecciona entre el grupo que consiste en -CN y -NO2 y el otro es Re; uno de R4a y R4b se selecciona entre el grupo que consiste en -CN y -NO2 y el otro es Rf; cada uno de R5 y R6 se selecciona independientemente entre el grupo que consiste en -H, -alquilo C1-6, -cicloalquilo C3-6, -CF3, -CHF2, -CH2F y -CH2OH; R7 se selecciona entre el grupo que consiste en -H, -CH3, -CF3, -CH2F, -CHF2 y -CH2OH; cada uno de Ra y Rb se selecciona independientemente entre el grupo que consiste en (a) -H, (b) halo, (c) -alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (d) -cicloalquilo C3-6, (e) -Oalquilo C1-3 opcionalmente sustituido con 1-3 de -F, (f) -OR8, (g) -CO2alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (h) -(CH2)nOR8, (i) -SR8 , (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 y (m) -NHSO2R8; cada uno de Rc y Rd se selecciona independientemente entre el grupo que consiste en (a) -H, (b) halo, (c) -alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (d) -cicloalquilo C3-6, (e) -Oalquilo C1-3 opcionalmente sustituido con 1-3 de -F, (f) -OR8, (g) -CO2alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (h) -(CH2)OR8, (i) -SR8, (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 y (m) -NHSO2R8; cada uno de Re y Rf se selecciona independientemente entre el grupo que consiste en (a) -H, (b) halo, (c) -alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (d) -cicloalquilo C3-6, (e) -Oalquilo C1-3 opcionalmente sustituido con 1-3 de -F, (f) -OR8, (g) - CO2alquilo C1-6 opcionalmente sustituido con 1-3 de -F, (h) -(CH2)nOR8 , (i) -SR , (j) -SOR8, (k) -SO2R8, (l) -NHCOR8 y (m) -NHSO2R8; n es un numero entero seleccionado entre 1, 2 y 3; y R8 se selecciona independientemente en cada caso entre el grupo que consiste en - H, -cicloalquilo C3-6 y -alquilo C1-6 opcionalmente sustituido con 1-3 de -F.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17584709P | 2009-05-06 | 2009-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076836A1 true AR076836A1 (es) | 2011-07-13 |
Family
ID=42244955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101504 AR076836A1 (es) | 2009-05-06 | 2010-05-04 | Inhibidores del canal de potasio medular externo renal |
Country Status (31)
Country | Link |
---|---|
US (2) | US8673920B2 (es) |
EP (1) | EP2427444B1 (es) |
JP (2) | JP5092068B2 (es) |
KR (1) | KR101373902B1 (es) |
CN (1) | CN102459216B (es) |
AR (1) | AR076836A1 (es) |
AU (1) | AU2010246269C1 (es) |
BR (1) | BRPI1014050A2 (es) |
CA (1) | CA2759399C (es) |
CL (1) | CL2011002761A1 (es) |
CO (1) | CO6460758A2 (es) |
CR (1) | CR20110578A (es) |
EA (1) | EA021008B1 (es) |
EC (1) | ECSP11011444A (es) |
ES (1) | ES2561654T3 (es) |
GE (1) | GEP20146055B (es) |
GT (1) | GT201100278A (es) |
HN (1) | HN2011002933A (es) |
IL (1) | IL215836A0 (es) |
MA (1) | MA33342B1 (es) |
MX (1) | MX337570B (es) |
MY (1) | MY157525A (es) |
NI (1) | NI201100193A (es) |
NZ (1) | NZ596229A (es) |
PE (1) | PE20120346A1 (es) |
SG (1) | SG175841A1 (es) |
TN (1) | TN2011000540A1 (es) |
TW (1) | TWI408135B (es) |
UA (1) | UA106611C2 (es) |
WO (1) | WO2010129379A1 (es) |
ZA (1) | ZA201108070B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012058116A1 (en) | 2010-10-27 | 2012-05-03 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2632464B1 (en) | 2010-10-29 | 2015-04-29 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
JP2014513116A (ja) | 2011-05-02 | 2014-05-29 | ゾエティス・エルエルシー | 抗菌剤として有用な新規セファロスポリン |
RU2014110401A (ru) | 2011-08-19 | 2015-09-27 | Мерк Шарп И Доум Корп. | Ингибиторы внешнего медуллярного калиевого канала почек |
WO2013039802A1 (en) * | 2011-09-16 | 2013-03-21 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US8999990B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US8999991B2 (en) | 2011-10-25 | 2015-04-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013066717A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2773351B1 (en) * | 2011-10-31 | 2017-08-23 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US9139585B2 (en) | 2011-10-31 | 2015-09-22 | Merck Sharp & Dohme Corp. | Inhibitors of the Renal Outer Medullary Potassium channel |
US9206199B2 (en) | 2011-12-16 | 2015-12-08 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2013102935A2 (en) * | 2012-01-03 | 2013-07-11 | Council Of Scientific & Industrial Research | Cu-MEDIATED ANNULATION FOR THE EFFECTIVE SYNTHESIS OF 3-SUBSTITUTED PHTHALIDES |
WO2014015495A1 (en) * | 2012-07-26 | 2014-01-30 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
AR092031A1 (es) | 2012-07-26 | 2015-03-18 | Merck Sharp & Dohme | Inhibidores del canal de potasio medular externo renal |
EP2925322B1 (en) * | 2012-11-29 | 2018-10-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2934533B1 (en) | 2012-12-19 | 2017-11-15 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
EP2956142B1 (en) | 2013-02-18 | 2017-09-20 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2014150132A1 (en) | 2013-03-15 | 2014-09-25 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2015017305A1 (en) | 2013-07-31 | 2015-02-05 | Merck Sharp & Dohme Corp | Inhibitors of the renal outer medullary potassium channel |
WO2015065866A1 (en) * | 2013-10-31 | 2015-05-07 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
US10000484B2 (en) | 2013-12-18 | 2018-06-19 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassim channel |
WO2015096035A1 (en) | 2013-12-24 | 2015-07-02 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2015103756A1 (en) * | 2014-01-09 | 2015-07-16 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
KR20160001316A (ko) | 2014-06-27 | 2016-01-06 | 조선대학교산학협력단 | 3d 조영기술을 이용한 환자 맞춤형 임플란트 모형제작방법 |
WO2016008064A1 (en) | 2014-07-14 | 2016-01-21 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
WO2016091042A1 (zh) * | 2014-12-08 | 2016-06-16 | 江苏恒瑞医药股份有限公司 | 吡啶甲酰胺类衍生物、其制备方法及其在医药上的应用 |
CN105693706B (zh) * | 2014-12-10 | 2019-11-22 | 江苏恒瑞医药股份有限公司 | 异苯并呋喃酮类衍生物、其制备方法及其在医药上的应用 |
US10513518B2 (en) | 2015-01-29 | 2019-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
WO2016127358A1 (en) | 2015-02-12 | 2016-08-18 | Merck Sharp & Dohme Corp. | Inhibitors of renal outer medullary potassium channel |
US10851108B2 (en) | 2016-04-20 | 2020-12-01 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
JP2019517494A (ja) * | 2016-06-07 | 2019-06-24 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腎髄質外層カリウムチャネル阻害剤としての医薬的に許容される塩 |
MA45857A (fr) | 2016-07-29 | 2021-05-19 | Sunovion Pharmaceuticals Inc | Composés et compositions, et utilisations associées |
CN106432214B (zh) * | 2016-08-09 | 2019-05-07 | 成都拿盛科技有限公司 | 一种制备romk通道抑制剂中间体的方法 |
WO2018093569A1 (en) | 2016-11-03 | 2018-05-24 | Bristol-Myers Squibb Company | Substituted bicycle heterocyclic derivatives useful as romk channel inhibitors |
CN110678463B (zh) | 2017-06-01 | 2023-06-06 | 百时美施贵宝公司 | 经取代的含氮化合物 |
WO2019016115A1 (en) * | 2017-07-21 | 2019-01-24 | BASF Agro B.V. | PROCESS FOR THE PREPARATION OF SUBSTITUTED ARYLE KETONES |
TWI685492B (zh) * | 2017-12-06 | 2020-02-21 | 大陸商江蘇恒瑞醫藥股份有限公司 | 腎外髓質分泌鉀通道抑制劑的晶型及其製備方法 |
CN109879863B (zh) * | 2017-12-06 | 2020-10-20 | 江苏恒瑞医药股份有限公司 | 一种肾外髓质分泌钾通道抑制剂的晶型及其制备方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2988551A (en) | 1954-07-30 | 1961-06-13 | Union Chimique Belge Sa | Piperazine derivatives |
GB949088A (en) | 1961-06-26 | 1964-02-12 | Lepetit Spa | Diazabicyclo-octane derivatives |
US3435002A (en) | 1967-05-15 | 1969-03-25 | Gen Electric | Polyamide acid resins and polyimides therefrom |
GB1575310A (en) | 1976-11-16 | 1980-09-17 | Anphar Sa | Piperidine derivatives |
FR2522325B1 (fr) | 1982-02-26 | 1985-08-09 | Delalande Sa | Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique |
NL8202636A (nl) | 1982-06-29 | 1984-01-16 | Gist Brocades Nv | Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten. |
EP0138754B1 (de) | 1983-08-15 | 1988-05-25 | Ciba-Geigy Ag | Photohärtbare Gemische |
US5145885A (en) | 1983-08-15 | 1992-09-08 | Ciba-Geigy Corporation | Photopolymerizable compositions containing aminoaryl ketone photoinitiators |
US4579863A (en) | 1983-12-06 | 1986-04-01 | Warner-Lambert Company | Substituted trans-1,2-diaminocyclohexyl amide compounds |
JPS6176476A (ja) * | 1984-09-21 | 1986-04-18 | Chugai Pharmaceut Co Ltd | キサントン誘導体 |
US4661607A (en) | 1984-09-21 | 1987-04-28 | Chugai Seiyaku Kabushiki Kaisha | Furoxanthone derivatives useful as diuretics |
GB8603120D0 (en) | 1986-02-07 | 1986-03-12 | Pfizer Ltd | Anti-dysrhythmia agents |
JPH0745471B2 (ja) * | 1986-12-04 | 1995-05-17 | 参天製薬株式会社 | ピペラジン誘導体 |
US5215989A (en) | 1989-12-08 | 1993-06-01 | Merck & Co., Inc. | Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents |
US5032604A (en) * | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Class III antiarrhythmic agents |
FR2673182A1 (fr) | 1991-02-22 | 1992-08-28 | Univ Caen | Piperazines n,n'-disubstituees, leur procede de preparation et leur application en therapeutique. |
CA2168264A1 (en) | 1993-07-28 | 1995-02-09 | Yoichi Kawashima | Novel 1, 4-(diphenylalkyl)piperazine derivatives |
KR960007560A (ko) * | 1994-08-16 | 1996-03-22 | 김정규 | 신규한 아민 유도체, 그의 제조방법 및 항부정맥제로서의 용도 |
US5614526A (en) | 1995-06-09 | 1997-03-25 | Hoffmann-La Roche Inc. | Use of phenoxy-piperzine derivatives |
WO1997044329A1 (en) | 1996-05-20 | 1997-11-27 | Teijin Limited | Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists |
DE19637237A1 (de) | 1996-09-13 | 1998-03-19 | Merck Patent Gmbh | Piperazin-Derivate |
JPH10203986A (ja) | 1997-01-22 | 1998-08-04 | Mitsubishi Chem Corp | 眼疾患用薬剤 |
EP1165082A4 (en) | 1999-03-03 | 2002-06-12 | Merck & Co Inc | PRENYLE PROTEIN TRANSFERASE INHIBITORS |
EP1094063A1 (en) | 1999-10-18 | 2001-04-25 | Applied Research Systems ARS Holding N.V. | 9-(Piperazinylalkyl)carbazoles as Bax-modulators |
PT1309591E (pt) | 2000-08-14 | 2007-04-30 | Ortho Mcneil Pharm Inc | Pirazoles substituídos |
US6693099B2 (en) | 2000-10-17 | 2004-02-17 | The Procter & Gamble Company | Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance |
SE0003795D0 (sv) * | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Pharmaceutically useful compounds |
GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
CN1172919C (zh) * | 2002-06-03 | 2004-10-27 | 上海医药工业研究院 | 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用 |
GB0220214D0 (en) | 2002-08-30 | 2002-10-09 | Novo Pharmaceuticals De Ltd | Compounds and their use |
US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
WO2004037817A1 (ja) | 2002-10-25 | 2004-05-06 | Mitsubishi Pharma Corporation | N−オキシド化合物 |
WO2004046110A1 (ja) | 2002-11-15 | 2004-06-03 | Yamanouchi Pharmaceutical Co., Ltd. | メラニン凝集ホルモン受容体拮抗剤 |
MXPA05010444A (es) | 2003-04-03 | 2005-11-04 | Merck Patent Gmbh | Compuestos de carbonilo. |
EP1608645B1 (de) | 2003-04-03 | 2007-05-02 | MERCK PATENT GmbH | Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid)-2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen |
DE10329457A1 (de) | 2003-04-03 | 2005-01-20 | Merck Patent Gmbh | Ethinylprolinderivate |
ATE337000T1 (de) | 2003-06-18 | 2006-09-15 | Merck Patent Gmbh | Pyrrolidin-1,2-dicarbonsäure-1- (4-ethinyl- phenyl)-amidö-2- (phenyl)-amidö derivate als inhibitoren der koagulationsfaktoren xa und viia zur behandlung von thrombosen |
WO2005019167A2 (en) | 2003-08-13 | 2005-03-03 | Amgen, Inc. | Melanin concentrating hormone receptor antagonist |
CN1897950A (zh) | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
WO2006034341A2 (en) | 2004-09-20 | 2006-03-30 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase |
DE102004045796A1 (de) | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
DE102004047254A1 (de) | 2004-09-29 | 2006-04-13 | Merck Patent Gmbh | Carbonylverbindungen |
WO2006098342A1 (en) | 2005-03-16 | 2006-09-21 | Astellas Pharma Inc. | Piperazinyl compounds |
GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
RU2405770C2 (ru) | 2005-09-27 | 2010-12-10 | Сионоги Энд Ко., Лтд. | Производное сульфонамида, обладающее антагонистической активностью в отношении рецептора pgd2 |
WO2007075629A2 (en) | 2005-12-21 | 2007-07-05 | Schering Corporation | Phenoxypiperidines and analogs thereof useful as histamine h3 antagonists |
WO2008147864A2 (en) | 2007-05-22 | 2008-12-04 | Xenon Pharmaceuticals Inc. | Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
EP2303850A4 (en) | 2008-06-13 | 2012-10-31 | Bionomics Ltd | NOVEL BLOCKERS OF THE POTASSIUM CHANNEL AND THEIR USES |
-
2010
- 2010-04-27 US US12/768,209 patent/US8673920B2/en active Active
- 2010-04-29 KR KR1020117029121A patent/KR101373902B1/ko active IP Right Grant
- 2010-04-29 UA UAA201114416A patent/UA106611C2/uk unknown
- 2010-04-29 PE PE2011001912A patent/PE20120346A1/es not_active Application Discontinuation
- 2010-04-29 AU AU2010246269A patent/AU2010246269C1/en not_active Ceased
- 2010-04-29 NZ NZ59622910A patent/NZ596229A/en not_active IP Right Cessation
- 2010-04-29 MX MX2011011741A patent/MX337570B/es active IP Right Grant
- 2010-04-29 EA EA201171361A patent/EA021008B1/ru not_active IP Right Cessation
- 2010-04-29 CA CA 2759399 patent/CA2759399C/en not_active Expired - Fee Related
- 2010-04-29 JP JP2012509848A patent/JP5092068B2/ja not_active Expired - Fee Related
- 2010-04-29 MA MA34422A patent/MA33342B1/fr unknown
- 2010-04-29 BR BRPI1014050-6A patent/BRPI1014050A2/pt not_active Application Discontinuation
- 2010-04-29 SG SG2011080090A patent/SG175841A1/en unknown
- 2010-04-29 EP EP10716982.3A patent/EP2427444B1/en active Active
- 2010-04-29 GE GEAP201012494A patent/GEP20146055B/en unknown
- 2010-04-29 MY MYPI2011005322A patent/MY157525A/en unknown
- 2010-04-29 CN CN201080030781.9A patent/CN102459216B/zh not_active Expired - Fee Related
- 2010-04-29 WO PCT/US2010/032872 patent/WO2010129379A1/en active Application Filing
- 2010-04-29 ES ES10716982.3T patent/ES2561654T3/es active Active
- 2010-05-04 AR ARP100101504 patent/AR076836A1/es unknown
- 2010-05-05 TW TW99114408A patent/TWI408135B/zh not_active IP Right Cessation
-
2011
- 2011-10-23 IL IL215836A patent/IL215836A0/en unknown
- 2011-10-24 TN TNP2011000540A patent/TN2011000540A1/en unknown
- 2011-11-03 ZA ZA2011/08070A patent/ZA201108070B/en unknown
- 2011-11-04 CL CL2011002761A patent/CL2011002761A1/es unknown
- 2011-11-04 HN HN2011002933A patent/HN2011002933A/es unknown
- 2011-11-04 NI NI201100193A patent/NI201100193A/es unknown
- 2011-11-07 CR CR20110578A patent/CR20110578A/es unknown
- 2011-11-08 EC ECSP11011444 patent/ECSP11011444A/es unknown
- 2011-11-11 CO CO11154161A patent/CO6460758A2/es not_active Application Discontinuation
- 2011-11-11 GT GT201100278A patent/GT201100278A/es unknown
-
2012
- 2012-09-12 JP JP2012200561A patent/JP5795755B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-24 US US14/162,963 patent/US9018211B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076836A1 (es) | Inhibidores del canal de potasio medular externo renal | |
AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
AR110400A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
PE20211788A1 (es) | Compuesto agonista de receptor thrb y metodo de preparacion y uso del mismo | |
PE20170925A1 (es) | Composiciones y metodos para el tratamiento de trastornos del snc | |
AR111813A2 (es) | Compuestos y composiciones para el control de nematodos | |
ECSP13012770A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina | |
UY32490A (es) | Inhibidores de beta-secretasa | |
AR084903A1 (es) | Derivados de aminodihidrotiazina fusionada | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR093659A1 (es) | Derivados ciclicos de nucleosidos y usos de los mismos | |
AR078408A1 (es) | Derivados de indol como moduladores de los crac | |
AR078495A1 (es) | Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico | |
AR063119A1 (es) | Derivados de piridinonas sustituidas, composiciones farmaceuticas que los contienen y usos como antagonistas en trastornos asociados a receptores del tipo i de la hormona de melanina(mch-1 o mchr-1) | |
AR100049A1 (es) | Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 | |
PE20181007A1 (es) | Derivados de indol mono-o disustituidos como inhibidores de la replicacion viral del dengue | |
AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
PH12015500400A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders | |
PE20170946A1 (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
AR066421A1 (es) | Compuestos derivados de piridona | |
CL2011003302A1 (es) | Compuestos derivados de amida del acido alquil-sulfonico; composicion farmaceutica; uso de los compuestos como moduladores de la disfuncion de glutamato para prevenir o tratar trastornos neurologicos y psiquiatricos como esquizofrenia, enfermedad de alzheimer, trastornos de deficit de atencion/hiperactividad, perdida de audicion, entre otros. | |
PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
AR105774A1 (es) | Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |